GLYC (GlycoMimetics, Inc.) Earnings growth in current year

GlycoMimetics, Inc. (GLYC) is undergoing a period of rigorous reorganization and asset consolidation following failures in clinical trials of its lead drug candidate. The annual trend in net income per share reflects the current market valuation, where 96.70 indicates the current level. Meanwhile, the patent portfolio in glycobiology is attracting strategic partners, protecting capital. A unique approach to cancer cell metabolism is laying the foundation for future revenues.

GLYC (GlycoMimetics Inc.) Earnings growth in current year history from 07/04/2022 to 06/16/2025

Comprehensive metric breakdowns and analytics for glycomimetics.com (GLYC)

- share price and expert price forecast:

Price GlycoMimetics|GLYC - Analyst Consensus Forecast

- business market valuation indicators:

Market Capitalization GlycoMimetics, Inc.|GLYC - Total Company Value

- book capitalization data:

Accounting Value of a Share GlycoMimetics|GLYC - Book Capitalization|Market Value to Equity Ratio glycomimetics.com|GLYC - Company Total Assets

- debt and liquidity details:

- net income and valuation multiples indicators:

GLYC - Net Income|Future Net Profit GlycoMimetics, Inc.|GLYC - P/E Multiple|Future Price to Earnings Multiple GlycoMimetics|GLYC - PEG Multiple|Company Value to EBITDA GlycoMimetics, Inc.|GLYC - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year GlycoMimetics|GLYC - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth glycomimetics.com|GLYC - Earnings per share growth in current year|Net earnings per share change forecast for next year GlycoMimetics, Inc.

- sales volume and revenue information:

GLYC - Company Sales|Company Expected Sales Volume GlycoMimetics|GLYC - P/S Multiple|Projected Price to Revenue GlycoMimetics, Inc.

Fundamental valuation:GLYC GlycoMimetics Corp

Signature product of GlycoMimetics, Inc.

Investors use this indicator to evaluate profit generation efficiency and business scaling rates. The metric is calculated as the percentage deviation of current net income per share from the value for the same period last year. For GlycoMimetics, Inc. (GLYC), costs associated with the environmental modernization of production impact final margins, which is directly reflected in the annual growth rate of net income per share.

Direct competitors

GMAB: Net earnings per one share growth for the current year|EXEL (Exelixis Corp) - Earnings growth in current year|Earnings growth in current year Nuvalent Therapeutics|Earnings per share growth in current year Kymera Therapeutics (KYMR)|IDYA (ideayabio.com) - Earnings per share increase in current year|Earnings growth in current year ELVN (Enliven Therapeutics, Inc.)|Net earnings per share change in current year ORIC Pharmaceuticals Inc|Relay Pharma - Earnings growth in current year|Earnings per share growth rate in current year Nurix Corp|TYRA (Tyra Biosciences, Inc.) - Net earnings per share growth this year|VSTM: Net earnings per one share growth for the current year|GLUE (Monte Rosa Therapeutics, Inc.) - Earnings growth in current year|Earnings per share growth rate in current year Cullinan Oncology CGEM|Earnings growth in current year IMRX|C4 Therapeutics Corp - Earnings per share growth this year|Black Diamond - Net earnings per share growth this year|Earnings per share increase in current year RPTX|PMVP: Net earnings per share growth this year|Karyopharm Therapeutics - Net earnings per one share growth for the current year|PPCB: Earnings growth in current year|Cyclacel - Earnings per share increase in current year|AADI (Aadi Bioscience Inc) - Earnings growth in current year|Earnings per share growth rate in current year Aileron ALRN|Earnings per share growth in current year Blueprint Medicines (BPMC)|SWTX (SpringWorks Therapeutics Inc.) - Earnings per share increase in current year